The role of oxidative stress in susceptibility to seizures has been the focus of several recent studies. The aim of the present study was to evaluate the antiepileptic effects of the free radical scavenger edaravone on EL mice, a strain that is highly susceptible to convulsive seizures.
Introduction
Epilepsy is one of the most common neurological disorders in humans. It is characterized by recurrent spontaneous seizures, either convulsive or nonconvulsive, and by synchronized abnormal electrical activities arising from a group of cerebral neurons or neuronal networks 1 3 .
The pathophysiological mechanisms of epilepsy are not yet fully understood, but recent studies have focused on the role of oxidative stress in epileptic seizures.
Oxidative reactions are maintained by complex systems composed of various antioxidants, including reduced glutathione (GSH) and superoxide dismutase (SOD). Of these, GSH is an important constituent of the cellular antioxidant defense mechanism; it reacts nonenzymatically with a variety of different free radicals 4 7 to change to an oxidized form, oxidized glutathione (GSSG), and the GSH/GSSG ratio serves as a sensitive index of oxidative stress 8, 9 . In addtion, GSH has been shown to protect neurons against glutamate-induced cytotoxicity, ischemic damage, and aging 10, 11 . Three SOD isozymes are also essentially involved in cellular defense against the oxidative processes occurring along with the generation of superoxide anion radicals 12 : extracellular SOD (EC-SOD), cytoplasmic copper-and zinc-containing SOD (Cu/Zn-SOD), and mitochondrial manganesecontaining SOD (Mn-SOD).
The EL mouse is an inbred mutant strain of the DDY mouse and is susceptible to convulsive seizures. The strain was developed in 1954 13 and was established with electroencephalography (EEG) as an authentic epileptic mutant in 1976 14 . Studies of EL mice show that decreased antioxidant protection or excessive free-radical formation is associated with a redox shift to an oxidized state 15 17 and elevated extracellular glutamate concentration caused by dysfunction of excitatory amino acid transporters 18, 19 .
Edaravone (MCI-186; 3-methyl-1-phenyl-2-pyrazolin-5one) is a scavenger of low-molecular-weight free radicals which readily crosses the blood-brain barrier 20 and exerts inhibitory effects on both water-soluble and lipid-soluble peroxyl radical-induced peroxidation systems 21 23 . Recent studies indicate that edaravone prevents kainic acidinduced neuronal death 24 and hippocampal damage after pilocarpine-induced status epilepticus 25 ; it also delays the development of amygdala kindling in rats 26 . However, no previous studies have investigated the antiepileptic effects of edaravone in EL mice. In the present study, we investigated the antioxidant potency of edaravone and used EEGs to assess changes in seizure susceptibility.
Materials and Methods

Edaravone
Edaravone was kindly supplied by Mitsubishi Tanabe Pharma Corporation (Osaka, Japan). For the present study, the drug (30 mg) was dissolved in 0.5 mL of 1 M NaOH and 8 mL of distilled water and titrated to pH 7.0 with 1 M HCl. The concentration was adjusted to 0.3 mg/mL or 3 mg/mL in 0.9% saline solution.
Animals
We used male EL mice (30 50 g) aged 90 days from an 
GSH and GSSG Assay
Nine mice were divided into 3 groups and were given 0.1 mL saline (controls) or 0.1 mL edaravone (1 or 10 mg/ kg/day) intraperitoneally for 1 week. They were then decapitated, and their brains were removed and placed on ice. The hippocampus was separated and weighed. Both GSH and GSSG were analyzed with a GSSG/GSH Quantification Kit (Dojindo Laboratories, Kumamoto, Japan).
The hippocampus was homogenized (10% w/v) in 5% sulfosalicylic acid and centrifuged at 8,000 g for 10 minutes at 4 . The supernatant was collected and diluted 20 times for GSH analysis, and 5 times for GSSG analysis.
Samples were incubated at 37 for 10 min, and absorbance was then measured at 405 nm with a microplate reader.
SOD Activity Assay
Other mice were prepared in the same way as for the GSH and GSSG assay, except that there was only one edaravone group, the members of which received 10 mg/ kg/day. The SOD activity was assayed with a SOD assay kit-WST (Dojindo Laboratories). The hippocampus was homogenized (10% w/v) in 10 mM Tris-HCl buffer (pH 7.4) with 0.25 M sucrose and 1 mM EDTA, and centrifuged at 10,000 g for 60 min at 4 . The supernatant was used for SOD activity analysis.
Anticonvulsive Effect of Edaravone
Once a week from the age of 28 days, mouse was taken carefully from its home cage, placed in a box (30× in the present study. These mice were intraperitoneally administered with edaravone (10 mg/kg/day) on 7 consecutive days. After intraperitoneal injections of edaravone for 7 consecutive days, they were subjected to tossing stimulation and the severity of the resulting seizures was determined.
EEG Preparation and Testing
Electrodes were implanted as previously described ( Fig. 1) 29 
Statistical Analysis
Data are presented as mean standard error of the mean (SEM), and the statistical significance of differences was determined with analysis of variance and Student's t-test.
Results
Evaluation of Hippocampal GSH and GSSG Levels
The GSH levels did not vary according to edaravone dosage (untreated, 3.07 0.05 μmol/g; 1 mg/kg/day edaravone, 3.16 0.05 μmol/g; and 10 mg/kg/day edaravone, 3.06 0.03 μmol/g) ( Fig. 2A) . Hippocampal GSSG levels in the mice treated with edaravone (1 mg/kg/day, 0.018 0.002 μmol/g; 10 mg/kg/day, 0.013 0.001 μmol/ g) were dose-dependently decreased, and levels in mice receiving 10 mg/kg/day edaravone were significantly lower than levels in control saline-treated mice (0.023 0.002 μmol/g, p<0.01) (Fig. 2B) . The GSH/GSSG ratio was dose-dependently increased by treatment with edaravone (1 mg/kg/day, 176.41 20.77; 10 mg/kg/day, 228. 18 4.38) and was significantly increased with treatment of 10 mg/kg/day over that without treatment with edaravone (153.83 23.96; p<0.05) (Fig. 2C) .
Evaluation of Hippocampal SOD Activity
Hippocampal EC-SOD and Cu/Zn-SOD activities were higher in the edaravone-treated mice (163.78% 40.66%) than in saline-treated control mice (100% 15.19%), but the increase was not statistically significant. No difference in Mn-SOD activity was observed between the control mice (100 9.45%) and the edaravone-treated mice (84.37% 8.05%) ( Fig. 3) .
Effect of Edaravone on Seizure Grades
Seizure grades in the edaravone-treated mice were 1.4 0.28 and indicated that edaravone significantly suppressed convulsive seizures (p<0.05) (Fig. 4) .
EEG Changes
The duration of interictal spike discharges was significantly shorter after treatment with edaravone (1.00 0.03 seconds) than before (1.78 0.07 seconds) ( Fig. 5, 6A) , but there was no statistical difference in the frequency of spike discharges (Fig. 6B) . The mean total duration time of interictal spike discharges after treatment showed a decreasing trend, but the difference was not statistically significant ( Fig. 6C ).
Discussion
The present study suggests that edaravone decreases seizure susceptibility by regulating oxidative stress in the hippocampus of EL mice.
Compared with nonepileptic DDY mice, EL mice have lower GSH levels and higher GSSG levels in the hippocampus 17 . Edaravone protects against various free radicals 21 , so reduced GSSG levels indicate a direct effect of edaravone on free radicals as a substitute for GSH. However, edaravone had no effect on the hippocampal GSH levels of the EL mice we used in our study, so it is possible that the GSH reacted with proteins containing redoxsensitive thiols: it is known that GSH reversibly modifies 35 . We observed increased GSH/GSSG ratios induced by edaravone, indicating reduced oxidative stress in the hippocampal tissues of EL mice. Therefore, we propose that edaravone modulates hippocampal neurotransmission by protecting glutamate transporters from oxidation.
Overexpression of Cu/Zn-SOD in transgenic mice exerts a major effect on neuronal excitability in the hippocampus 36 . The Cu/Zn-SOD activity in EL mice de-creases as epileptogenesis progresses 15 . These effects suggest that Cu/Zn-SOD activities are associated with the regulation of neuronal excitability, and our present findings indicate that edaravone increases hippocampal Cu/ Zn-SOD activities and decreases seizure susceptibility in EL mice. Therefore, we believe that the reversible thiol modifications due to GSH and the increasing Cu/Zn-SOD activities reduce the seizure susceptibility of EL mice.
Our results suggest that edaravone has potent antiepileptic effects on EL mice. Further studies are needed to clarify whether edaravone affects seizure susceptibility at a genetic level or via neurotransmitters, such as glutamate and gamma-aminobutyric acid.
